aibioTaysha derivative suit over 2023 private placement faces termination motion
Tickers TSHA
Stockholders sued in Delaware Chancery over the August 2023 private placement. A special litigation committee moved on March 3, 2026 to end the case, and the lead plaintiff does not oppose.
Key facts
- Company
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
- News type
- Legal
- Primary source
- Taysha Gene Therapies 10-Q for the quarter ended June 30, 2026 (SEC EDGAR)
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) said in its 10-Q filed August 11, 2026 that a special litigation committee of its board has moved to terminate a consolidated stockholder derivative case over the company's August 2023 private placement, and that the lead plaintiff does not oppose the motion. Stockholders filed the original suits in January 2024 and April 2024 in the Court of Chancery of the State of Delaware. Taysha is the nominal defendant, and the complaints seek damages in its favor. The 10-Q gives no case caption or number.
The 10-Q does not name the defendants. It describes them as "certain of the Company's current and former directors and officers" and "certain participants in the Company's August 2023 Private Placement." Taysha's 10-K signed March 19, 2024, the nearest annual report to the first suit, shows a board of Sean Nolan, Phillip B. Donenberg, Sean Stalfort, Sukumar Nagendran, M.D., Alison Long, M.D., Ph.D., and Laura Sepp-Lorenzino, Ph.D. Nolan was also chief executive officer, and Kamran Alam was chief financial officer. No filing we reviewed says which individuals are sued.
The case
The first complaint, filed in January 2024, asserted claims against certain current and former directors for breach of fiduciary duty and unjust enrichment relating to the August 2023 private placement. A second stockholder suit followed in April 2024, and the court consolidated them and appointed a lead plaintiff.
In October 2024, the lead plaintiff filed an amended complaint with two sets of claims about the private placement. The first, against certain directors and officers, is for breach of fiduciary duty and unjust enrichment. The second, against certain participants in the placement, is for aiding and abetting breach of fiduciary duty and unjust enrichment. The complaints seek an unspecified award of damages in the company's favor, pre-judgment and post-judgment interest, and costs and disbursements, including fees for the plaintiffs' attorneys and experts.
Defendants
The defendants are certain current and former directors and officers and certain private placement participants, and the 10-Q names none of them. The March 2024 10-K lists Nolan as chief executive officer and director, Alam as chief financial officer, and five other directors. Because the amended complaint also reaches former directors and officers, that list may not match the people sued.
Where it stands
Taysha's board formed a special litigation committee to investigate the claims in the amended complaint. On March 3, 2026, the committee moved to terminate the action, stating its conclusion that dismissal is in the best interest of the company and its stockholders. On April 1, 2026, the lead plaintiff filed a response stating that he does not oppose the motion. The 10-Q reports no ruling by the court.
Why it matters to shareholders
Taysha has not recorded a liability for the lawsuits. The 10-Q says the company cannot reasonably estimate possible losses or gains or determine whether an unfavorable outcome is probable or remote. Taysha also says it indemnifies its directors, officers, employees, licensors, suppliers and service providers under contracts in the normal course of business. Its maximum exposure under those arrangements is unknown at June 30, 2026, and it does not anticipate recognizing any significant losses.
Related matters
In a related Securities and Exchange Commission investigation captioned In the Matter of Taysha Gene Therapies, Inc. (D-04192), Taysha and certain of its officers and directors received subpoenas in late 2024 for materials relating to the August 2023 private placement and certain public offerings. The company completed its production in April 2025. In June 2026, the SEC told the company and each named officer and director that it was terminating the investigation and did not intend to recommend any enforcement actions.